Loading organizations...
Ajinomoto develops and manufactures food products, seasonings, and amino acid-based solutions. Known for AJI-NO-MOTO®, its original umami seasoning, its offerings include processed foods, beverages, and nutritional supplements. Applying amino science expertise, Ajinomoto creates diverse products across food, health, and biotechnology sectors, aiming to enhance global well-being.
Founded in 1908 by Japanese chemist Dr. Kikunae Ikeda, who discovered "umami" by isolating glutamic acid from kombu. Driven to improve public nutrition, Ikeda partnered with entrepreneur Saburosuke Suzuki II. This led to the 1909 launch of AJI-NO-MOTO®, the world's first umami seasoning, establishing the Ajinomoto Group.
Ajinomoto serves global consumers, food industries, and healthcare providers with products enhancing taste, nutrition, and health. Its vision, "Eat Well, Live Well," emphasizes amino acid potential. It addresses global food and health challenges through scientific and product innovations, striving for a better quality of life worldwide.
Key people at Ajinomoto.
Key people at Ajinomoto.
Ajinomoto has 5 tracked investments across 5 companies. The latest tracked deal is $5.0M Series A in Enhanced Medical Nutrition in January 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 14, 2025 | Enhanced Medical Nutrition | $5.0M Series A | Ajinomoto | — |
| Mar 27, 2024 | TechMagic | $16.8M Series C | — | Oriental Land Innovations, 相原直也, Shoko Chukin Bank, 宇佐美大典 |
| May 1, 2023 | Ascend Gene & Cell Therapies | $66.0M Series A | Abingworth, Michael Beecham | ED Mathers, Rivervest, Andrew Kozlov, JIA YI HAR, Eric Shiozaki, Deerfield Management, Digitalis Ventures |
| Apr 19, 2021 | DAIZ | $17.0M Series B | — | Eneos Innovation Partners, Global Brain, Golden Asia Fund II, Kanematsu Corporation, Kemuri Ventures, Kichiri, Kirin Holdings, Marubeni Corporation, Mitsui Sumitomo Insurance Venture Capital, Nippon Steel Trading, Norinchukin Bank, QB Capital, Shinkin Capital |
| Oct 18, 2017 | MycoTechnology | $42.0M Series B | — | Continental Grain Company, Health For Life Capital, Middleland Capital, S2G Ventures |
